Literature DB >> 8513583

Characterization of anti-acetylcholine receptor (AChR) antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis (EAMG).

Y M Graus1, P J van Breda Vriesman, M H de Baets.   

Abstract

In the murine model for EAMG we investigated the relation between disease susceptibility and fine specificity of anti-AChR antibodies obtained from high susceptible C57Bl/6 and low susceptible BALB/c mice after immunization with Torpedo acetylcholine receptor (tAChR). Anti-AChR MoAbs with fine specificity for the main immunogenic region (MIR), the alpha-bungarotoxin (alpha-BT)/acetylcholine binding sites and other extra- and intracellular epitopes were isolated from both mouse strains. In total, nine out of 38 MoAbs obtained from C57Bl/6 mice were directed against extracellular epitopes on mouse AChR in contrast to only one out of 27 MoAbs from BALB/c mice. A difference in antibody repertoire may underlie the difference in pathogenic response observed between these mouse strains. These results indicate that strain-specific differences in disease susceptibility in murine EAMG may be related to differences in the available repertoire of potential pathogenic antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513583      PMCID: PMC1554759          DOI: 10.1111/j.1365-2249.1993.tb03429.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Strain differences in the autoimmune response of mice to acetylcholine receptors.

Authors:  S Fuchs; D Nevo; R Tarrab-Hazdai; I Yaar
Journal:  Nature       Date:  1976-09-23       Impact factor: 49.962

2.  Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations.

Authors:  A G Engel; E H Lambert; F M Howard
Journal:  Mayo Clin Proc       Date:  1977-05       Impact factor: 7.616

3.  Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.

Authors:  R R Almon; C G Andrew; S H Appel
Journal:  Science       Date:  1974-10-04       Impact factor: 47.728

4.  Functional consequences of engagement of the T cell receptor by low affinity ligands.

Authors:  J Alexander; K Snoke; J Ruppert; J Sidney; M Wall; S Southwood; C Oseroff; T Arrhenius; F C Gaeta; S M Colón
Journal:  J Immunol       Date:  1993-01-01       Impact factor: 5.422

5.  Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis.

Authors:  V A Lennon; M E Seybold; J M Lindstrom; C Cochrane; R Ulevitch
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

6.  Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.

Authors:  J M Lindstrom; M E Seybold; V A Lennon; S Whittingham; D D Duane
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

7.  Modulation of acetylcholine receptor by antibody against the receptor.

Authors:  S Heinemann; S Bevan; R Kullberg; J Lindstrom; J Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

8.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation.

Authors:  I Kao; D B Drachman
Journal:  Science       Date:  1977-04-29       Impact factor: 47.728

9.  Experimental myasthenia gravis. A murine system.

Authors:  P W Berman; J Patrick
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

10.  Binding of antibodies to acetylcholine receptors in Electrophorus and Torpedo electroplax membranes.

Authors:  A Karlin; E Holtzman; R Valderrama; V Damle; K Hsu; F Reyes
Journal:  J Cell Biol       Date:  1978-03       Impact factor: 10.539

View more
  7 in total

Review 1.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

2.  IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice.

Authors:  Ruksana Huda; Richard T Strait; Erdem Tüzün; Fred D Finkelman; Premkumar Christadoss
Journal:  J Neuroimmunol       Date:  2015-03-06       Impact factor: 3.478

3.  Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals.

Authors:  F D Shi; X F Bai; H L Li; Y M Huang; P H Van der Meide; H Link
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

4.  Optimization of a murine immunization model for study of PF4/heparin antibodies.

Authors:  S Suvarna; R Qi; G M Arepally
Journal:  J Thromb Haemost       Date:  2009-02-24       Impact factor: 5.824

5.  SHIP represses lung inflammation and inhibits mammary tumor metastasis in BALB/c mice.

Authors:  Melisa J Hamilton; Elizabeth C Halvorsen; Nancy E LePard; Momir Bosiljcic; Victor W Ho; Vivian Lam; Judit Banáth; Kevin L Bennewith; Gerald Krystal
Journal:  Oncotarget       Date:  2016-01-26

6.  Characterization of pathogenesis of and immune response to Burkholderia pseudomallei K96243 using both inhalational and intraperitoneal infection models in BALB/c and C57BL/6 mice.

Authors:  Jeremy J Bearss; Melissa Hunter; Jennifer L Dankmeyer; Kristen A Fritts; Christopher P Klimko; Chris H Weaver; Jennifer L Shoe; Avery V Quirk; Ronald G Toothman; Wendy M Webster; David P Fetterer; Joel A Bozue; Patricia L Worsham; Susan L Welkos; Kei Amemiya; Christopher K Cote
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

7.  Use of Toll-Like Receptor Agonists to Induce Ectopic Lymphoid Structures in Myasthenia Gravis Mouse Models.

Authors:  Marieke Robinet; Bérengère Villeret; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Front Immunol       Date:  2017-08-25       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.